Sonoma Pharmaceuticals, Inc. Logo

Print Print page | Email Email page | PDF Download PDF | Add to Briefcase Add to briefcase
« Previous Release | Next Release »



Sonoma Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2017

Conference Call Begins at 4:30pm EDT Today

PETALUMA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced financial results for the fourth quarter and the fiscal year 2017, ended March 31, 2017 and provided a corporate update.

Total revenue was $4 million for the fourth quarter as compared to $2.6 million for the same period last year.  Product revenues of $3.8 million were up 60%, or $1.4 million, when compared to the same period last year, driven by strong growth in the U.S. and international markets. The numbers in this press release reflect the reclassification of the financial components of the Latin American operations as a discontinued business due to the sale of this business. (See the section below on "Sale of Latin American Business and Impact on Accounting Treatment" for more details.)

"We are pleased with the progress we have made this year in executing on our corporate strategy of growing dermatology revenue with our expanding direct sales force," said Jim Schutz, Sonoma Pharmaceuticals CEO. "This progress is evidenced by our current robust product portfolio and 86% growth in prescriptions filled for FY 2017, compared to last year. Our growing sales force coupled with planned product launches provide a high level of confidence in our future growth.  Looking forward, with our strong cash position of $17.5 million, we believe we have more than sufficient cash to fully fund our high sales growth plan and achieve breakeven without diluting shareholders."

Business Highlights:

Financial Highlights:

Product revenues in the United States for the quarter ended March 31, 2017, of $1.8 million, increased by $451,000, or 32%, when compared to the same period in the prior year. This increase was the result of higher sales of the company's dermatology and animal healthcare products. In addition, sales to a new animal health care partner increased during the quarter compared to last year, partially offset by a decline in U.S. wound care revenue.

Product revenue in Latin America for the quarter ended March 31, 2017, was $834,000. This amount reflects the sale of products to Invekra, at reduced or previously agreed to prices, since completion of Sonoma's asset sale to Invekra in October 2016.  Sonoma will continue to supply Invekra until its manufacturing facility is operational.

Product revenue in Europe and the rest of the world for the quarter ended March 31, 2017, of $1.1 million, increased by $145,000 or 15%, as compared to the same period in the prior year, with increases in Asia, partially offset by decreases in the Middle East and Europe.

Sonoma reported gross profit of $1.9 million, or 48% of total revenue, during the three months ended March 31, 2017, compared to a gross profit of $971,000, or 38% of total revenue when compared to the same period in the prior year. The gross profit percentage increased as compared to last year, primarily due to the reclassification of gross margin between the continuing and discontinued operations.

Total operating expenses of $4.9 million for the three months ended March 31, 2017, increased by $273,000, or 6%, as compared to the same period in the prior year. Operating expenses minus non-cash expenses during the fourth quarter of fiscal year 2017 were $4.5 million, up $361,000, or 9%, as compared to the same period in the prior year. This increase in operating expenses was mostly due to higher sales, marketing and administrative expenses in the United States related to the growth of a direct sales force in dermatology, partly offset by a decline in European expenses.  A key driver to the growth in operating expenses was the increase in the number of sales representatives, compared to the same period last year.

Net loss from continuing operations for the quarter ended March 31, 2017, was $2.9 million, a decrease of $737,000 as compared to net loss from continuing operations of $3.7 million for the same period in the prior year. The operating loss minus non-cash expenses was $2.4 million, down $750,000, compared to $3.2 million for the same period last year.  

As of March 31, 2017, Sonoma had cash and cash equivalents of $17.5 million, as compared with $7.5 million as of March 31, 2016.

Results for the Twelve Months Ended March 31, 2017
Total revenues of $12.8 million increased by $3.4 million, or 37%, for the twelve months ended March 31, 2017, as compared to $9.4 million for the twelve months ended March 31, 2016. Product revenue of $12 million increased $3.9 million, or 48%, as compared to $8.1 million for the twelve months ended March 31, 2016. The increase in product revenue was driven by strong growth in the United States, up $2.2 million, or 51%, and in international markets, up 45%.

Sonoma reported gross profit of $5.7 million, or 44% of total revenue, for the twelve months ended March 31, 2017, compared to a gross profit of $2.6 million, or 28% of total revenue when compared to the same period in the prior year. The gross profit percentage increased, compared to last year primarily due to the reclassification of gross margin between the continuing and discontinued operations.

Total operating expenses of $18.6 million for the twelve months ended March 31, 2017, increased by $1.3 million, or 7%, as compared to the same period in the prior year. Total operating expenses minus non-cash expenses of $16.6 million increased $1.2 million, or 8%, for the twelve months ended March 31, 2017, compared to the same period in the prior year. This increase was primarily due to higher costs of the direct sales force for dermatology. Operating loss minus non-cash expenses (EBITDA) for the twelve months ended March 31, 2017, was $10.5 million, compared to $12.4 million for the same period last year.

Conference Call
Sonoma's management will hold a conference call today to discuss fourth quarter fiscal year 2017 results and answer questions, beginning at 4:30 p.m. EDT. Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers.  Those interested in listening to the conference call live via the Internet may do so at http://ir.sonomapharma.com/events.cfm.  Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.

A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 15350781. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.

Sale of Latin American Business and Impact on Accounting Treatment
With the sale of the Latin American business during the third quarter, ended December 31, 2016, the components of the financial statements related to this transaction have been classified as a discontinued business for accounting purposes and in accordance with this accounting treatment, the income statement and balance sheet have been retroactively revised to reflect the revenue, expenses and balance sheet items of the continuing businesses for this fiscal year and last fiscal year.  All of the income statement categories related to Latin America have been condensed to a one line item on the income statement as "Income from discontinued operations."  Also, the discontinued balance sheets items have been listed separately from the continuing operations. As a result, the comparison of results discussed in this press release relate primarily to the continuing businesses in accordance with generally accepted accounting principles. 

About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.

Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "Company"). These forward-looking statements are identified by the use of words such as "believe," "achieve," and "strive," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies,  as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. 



SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
 
    March 31 
    2017   2016 
ASSETS          
Current assets:          
Cash and cash equivalents   $17,461  $7,469 
Accounts receivable, net    2,108   1,508 
Inventories, net    2,221   1,595 
Prepaid expenses and other current assets    616   1,505 
Current portion of deferred consideration, net of discount    237   - 
Current assets of discontinued operations    -   811 
Total current assets    22,643   12,888 
Property and equipment, net    1,239   850 
Deferred consideration, net of discount, less current portion    1,497   - 
Other assets    80   65 
Total assets   $25,459  $13,803 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable   $1,255  $1,337 
Accrued expenses and other current liabilities    1,302    1,526 
Deferred revenue    345   274 
Deferred revenue Invekra    176   - 
Current portion of long-term debt    123   114 
Current portion of capital leases    74   - 
Taxes payable    13   - 
Current liabilities of discontinued operations    -   300 
Total current liabilities    3,288   3,551 
Long-term deferred revenue Invekra    527   - 
Long-term debt, less current portion    45   - 
Long-term capital leases, less current portion    168   - 
Long-term liabilities of discontinued operations    -    112 
Total liabilities    4,028   3,663 
Commitments and contingencies          
Stockholders' equity          
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized, none issued and
outstanding at March 31, 2017 and March 31, 2016, respectively
    -   - 
Common stock, $0.0001 par value; 12,000,000 shares authorized at March 31, 2017and March 31,
2016, 4,289,322 and 4,196,873 shares issued and outstanding at
March 31, 2017 and March 31, 2016, respectively
    1   1 
Additional paid-in capital    168,709   166,368 
Accumulated deficit    (143,101)  (152,375)
Accumulated other comprehensive loss    (4,178)  (3,854)
Total stockholders' equity    21,431   10,140 
Total liabilities and stockholders' equity   $25,459  $13,803 


SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
 (In thousands, except per share amounts)
 
  Three Months Ended
March 31,
   Twelve Months Ended
March 31,
 
  2017  2016  2017  2016 
Revenues            
Product $3,799  $2,369  $11,957  $8,077 
Product licensing fees and royalties  -   -   -   231 
Service  230   206   868   1,061 
Total revenues  4,029   2,575   12,825   9,369 
Cost of revenues                
Product  1,912   1,438   6,419   5,840 
Service  170   166   738   881 
Total cost of revenues  2,082    1,604   7,157   6,721 
Gross profit  1,947   971   5,668   2,648 
Operating expenses                 
Research and development  350   441   1,576   1,806 
Selling, general and administrative  4,509   4,145   17,066   15,556 
Total operating expenses  4,859   4,586   18,642   17,362 
Loss from operations  (2,912)  (3,615)  (12,974)  (14,714)
Interest expense  (1)  (3)  (3)  (3)
Interest income  14   1   22   2 
Gain due to change in fair value of derivative liabilities  -   1   -   11 
Tax benefit  228   -   4,268   - 
Other income (expense), net  (258)  (50)  18   (20)
Loss from continuing operations  (2,929)  (3,666)  (8,669)  (14,724)
Income from discontinued operations (net of tax)  493   756   17,943   4,562 
Net income (loss) $(2,436) $(2,910) $9,274  $(10,162)
                  
Net income (loss) per share: basic and diluted                
Continuing operations $(0.69)  $(1.03) $(2.03) $(4.48)
Discontinued operations  0.12   0.21   4.20   1.39 
  $(0.57) $(0.82) $2.17  $(3.09)
                 
Weighted-average number of shares used in per share calculations: basic and diluted  4,224   3,565   4,270   3,289 
                 
Other comprehensive income (loss)                
Net income (loss) $(2,436) $(2,910) $9,274  $(10,162)
Foreign currency translation adjustments  493   45   (324)  (347)
Comprehensive income (loss) $(1,943) $(2,865) $8,950  $(10,509)


SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
(In thousands) and (Unaudited)
 
     Three Months Ended
March 31,
  Twelve Months Ended
March 31,
 
     2017  2016  2017  2016 
(1) Loss from operations minus non-cash expenses (EBITDA):                   
GAAP loss from operations as reported    $(2,912) $(3,615) $(12,974) $(14,714)
Non-cash adjustments:                   
Stock-based compensation     413   374   2,243   2,023 
Depreciation and amortization     70   62   248   244 
Non-GAAP loss from operations minus non-cash expenses (EBITDA)                $(2,429) $(3,179) $(10,483) $(12,447)
                    
(2) Net loss minus non-cash expenses:                                 
GAAP net income (loss) as reported    $(2,436) $(2,910) $9,274  $(10,162)
Non-cash adjustments:                   
Stock-based compensation     413   374   2,243   2,023 
Depreciation and amortization     70   62   248   244 
Gain due to change in fair value of derivative instruments     -   (1)  -   (11)
Non-GAAP net income (loss) minus non-cash expenses    $(1,953) $(2,475) $11,765  $(7,906)
                     
(3) Operating expenses minus non-cash expenses                   
GAAP operating expenses as reported    $4,859  $4,586  $18,642  $17,362 
Non-cash adjustments:                   
Stock-based compensation     (362)  (453)  (1,995   (1,913)
Depreciation and amortization     (12)  (9)  (42)  (44)
Non-GAAP operating expenses minus non-cash expenses    $4,485  $4,124  $16,605  $15,405 
 
  1. Loss from operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The Company defines operating loss minus non-cash expenses as GAAP reported operating loss minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period.

  2. Net loss minus non-cash expenses is a non-GAAP financial measure. The Company defines net loss minus non-cash expenses as GAAP reported net loss minus depreciation and amortization, stock-based compensation, a change in fair value of common stock, a change in the fair value of derivative instruments, loss on impairment of investment, and non-cash interest expense. The Company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period.

  3. Operating expenses minus non-cash expenses is a non-GAAP financial measure. The Company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The Company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period.


SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES
PRODUCT RELATED REVENUE SCHEDULES
(In thousands) and (Unaudited)
 
The following table shows the company's product revenues by geographic region:
 
   Three Months Ended March 31,      
                                            2017       2016        $ Change       % Change
 
United States                            $1,839  $1,388  $451   32%
Latin America   834   -   834   100%
Europe and Rest of the World   1,126   981   145   15%
Total  $3,799  $2,369  $1,430   60%
                  
   Twelve Months Ended March 31,         
      2017       2016       $ Change       % Change  
United States  $6,580  $4,371  $2,209   51%
Latin America   1,299   -   1,299   100%
Europe and Rest of the World   4,078   3,706   372   10%
    11,957   8,077   3,880   48%
Product license fees and royalties   -   231   (231)  (100)%
Total  $11,957  $8,308  $3,649   44%
                  
Media and Investor Contact:



Sonoma Pharmaceuticals, Inc.



Dan McFadden

VP of Public and Investor Relations

(425) 753-2105

dmcfadden@Sonomais.com

Primary Logo

Source: Sonoma Pharmaceuticals, Inc.

News Provided by Acquire Media

Close window | Back to top